These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

293 related articles for article (PubMed ID: 26384117)

  • 1. Fecal pyruvate kinase is not suitable for discrimination between inflammatory bowel disease exacerbation and acute gastroenteritis.
    Czub E; Nowak JK; Moczko J; Mankowski P; Lisowska A; Banaszkiewicz A; Banasiewicz T; Walkowiak J
    Dev Period Med; 2015; 19(2):167-73. PubMed ID: 26384117
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of fecal pyruvate kinase isoform M2 and calprotectin in assessment of pediatric inflammatory bowel disease severity and activity.
    Czub E; Nowak JK; Szaflarska-Poplawska A; Grzybowska-Chlebowczyk U; Landowski P; Moczko J; Adamczak D; Mankowski P; Banasiewicz T; Plawski A; Walkowiak J
    Acta Biochim Pol; 2014; 61(1):99-102. PubMed ID: 24649481
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fecal M2-pyruvate kinase (M2-PK): a novel marker of intestinal inflammation.
    Chung-Faye G; Hayee B; Maestranzi S; Donaldson N; Forgacs I; Sherwood R
    Inflamm Bowel Dis; 2007 Nov; 13(11):1374-8. PubMed ID: 17577247
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fecal pyruvate kinase: a potential new marker for intestinal inflammation in children with inflammatory bowel disease.
    Czub E; Herzig KH; Szaflarska-Popawska A; Kiehne K; Socha P; Woś H; Kamińska B; Błaszczyński M; Cichy W; Bała G; Brodzicki J; Grzybowska-Chlebowczyk U; Walkowiak J
    Scand J Gastroenterol; 2007 Oct; 42(10):1147-50. PubMed ID: 17852864
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The usefulness of fecal calprotectin in assessing inflammatory bowel disease activity.
    Lee YW; Lee KM; Lee JM; Chung YY; Kim DB; Kim YJ; Chung WC; Paik CN
    Korean J Intern Med; 2019 Jan; 34(1):72-80. PubMed ID: 29347813
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of a novel fecal marker--fecal tumor pyruvate kinase type M2 (M2-PK) with fecal calprotectin in patients with inflammatory bowel disease: a prospective study.
    Shastri YM; Povse N; Schröder O; Stein J
    Clin Lab; 2008; 54(9-10):389-90. PubMed ID: 19097497
    [No Abstract]   [Full Text] [Related]  

  • 7. Faecal S100A12 as a non-invasive marker distinguishing inflammatory bowel disease from irritable bowel syndrome.
    Kaiser T; Langhorst J; Wittkowski H; Becker K; Friedrich AW; Rueffer A; Dobos GJ; Roth J; Foell D
    Gut; 2007 Dec; 56(12):1706-13. PubMed ID: 17675327
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fecal Matrix Metalloprotease-9 and Lipocalin-2 as Biomarkers in Detecting Endoscopic Activity in Patients With Inflammatory Bowel Diseases.
    Buisson A; Vazeille E; Minet-Quinard R; Goutte M; Bouvier D; Goutorbe F; Pereira B; Barnich N; Bommelaer G
    J Clin Gastroenterol; 2018 Aug; 52(7):e53-e62. PubMed ID: 28723856
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of fecal pyruvate kinase isoform M2 and calprotectin in acute diarrhea in hospitalized children.
    Czub E; Nowak JK; Moczko J; Lisowska A; Banaszkiewicz A; Banasiewicz T; Walkowiak J
    Sci Rep; 2014 Apr; 4():4769. PubMed ID: 24759699
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fecal calprotectin in assessing inflammatory bowel disease endoscopic activity: a diagnostic accuracy meta-analysis.
    Rokkas T; Portincasa P; Koutroubakis IE
    J Gastrointestin Liver Dis; 2018 Sep; 27(3):299-306. PubMed ID: 30240474
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Faecal calprotectin testing for differentiating amongst inflammatory and non-inflammatory bowel diseases: systematic review and economic evaluation.
    Waugh N; Cummins E; Royle P; Kandala NB; Shyangdan D; Arasaradnam R; Clar C; Johnston R
    Health Technol Assess; 2013 Nov; 17(55):xv-xix, 1-211. PubMed ID: 24286461
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of three commercial fecal calprotectin ELISA test kits used in patients with Inflammatory Bowel Disease.
    Mirsepasi-Lauridsen HC; Bachmann Holmetoft U; Ingdam Halkjær S; Angeliki Krogfelt K; Munk Petersen A
    Scand J Gastroenterol; 2016; 51(2):211-7. PubMed ID: 26359672
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Faecal calprotectin as a novel biomarker for differentiating between inflammatory bowel disease and irritable bowel syndrome.
    Chang MH; Chou JW; Chen SM; Tsai MC; Sun YS; Lin CC; Lin CP
    Mol Med Rep; 2014 Jul; 10(1):522-6. PubMed ID: 24788223
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Validation of a point-of-care desk top device to quantitate fecal calprotectin and distinguish inflammatory bowel disease from irritable bowel syndrome.
    Sydora MJ; Sydora BC; Fedorak RN
    J Crohns Colitis; 2012 Mar; 6(2):207-14. PubMed ID: 22325175
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fecal Calprotectin as an Activity Marker of Inflammatory Bowel Disease in Children.
    Krzesiek E
    Adv Clin Exp Med; 2015; 24(5):815-22. PubMed ID: 26768632
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rapid fecal calprotectin test for prediction of mucosal inflammation in ulcerative colitis and Crohn disease: a prospective cohort study.
    Moniuszko A; Głuszek S; Rydzewska G
    Pol Arch Intern Med; 2017 May; 127(5):312-318. PubMed ID: 28442699
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Usefulness of a novel and rapid assay system for fecal calprotectin in pediatric patients with inflammatory bowel diseases.
    Inoue K; Aomatsu T; Yoden A; Okuhira T; Kaji E; Tamai H
    J Gastroenterol Hepatol; 2014; 29(7):1406-12. PubMed ID: 24635100
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Elevated fecal M2-pyruvate kinase in children with cystic fibrosis: a clue to the increased risk of intestinal malignancy in adulthood?
    Pang T; Leach ST; Katz T; Jaffe A; Day AS; Ooi CY
    J Gastroenterol Hepatol; 2015 May; 30(5):866-71. PubMed ID: 25376228
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rapid Fecal Calprotectin Test and Symptom Index in Monitoring the Disease Activity in Colonic Inflammatory Bowel Disease.
    Puolanne AM; Kolho KL; Alfthan H; Ristimäki A; Mustonen H; Färkkilä M
    Dig Dis Sci; 2017 Nov; 62(11):3123-3130. PubMed ID: 28948412
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Relationship of clinical symptoms with biomarkers of inflammation in pediatric inflammatory bowel disease.
    Hoekman DR; Diederen K; Koot BG; Tabbers MM; Kindermann A; Benninga MA
    Eur J Pediatr; 2016 Oct; 175(10):1335-42. PubMed ID: 27573259
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.